



## Chelsea and Westminster Hospital NHS Foundation Trust Trust Medicines Group

### Summary of Main Points from the Meeting held on Monday 25<sup>th</sup> September 2023

#### 2. Minutes and Summary Notes from last meeting

This meeting was held via Teams. The Minutes and Summary notes of the Medicines Group Meeting held on 10<sup>th</sup> July 2023 were approved. The summary notes will be disseminated and published on the Trust intranet. A quarterly summary report will be drafted and forwarded to the Trust Patient Safety Group meeting for inclusion on the agenda in due course.

#### 3. Matters Arising

The Group noted the matters arising from the previous meeting.

#### 4. Business to be transacted by the Medicines Group

##### 4.1 Formulary Applications

##### **Full Applications**

- **Epiduo<sup>®</sup> Forte Gel (Adapalene 0.3% and Benzoyl Peroxide 2.5%)**

Requested by: Dermatology

Indication: Cutaneous treatment of *Acne vulgaris*, when comedones, numerous papules and pustules are present for patients from 12 years of age and older.

Proposal: Add to the formulary

Rational: To be used as a 1st line, in line with NICE guidelines for the management of acne; or 2nd line in patients not responding to weaker preparations.

Cost: £19.53 for 45g

Likely to treat 45 patients per year cross site

Included on the NWL Integrated Formulary for requested indication.

**Outcome: Approved for addition to the Trust Formulary**

- **Trifarotene 50mcg/g Cream (Aklief<sup>®</sup>)**

Requested by: Dermatology

Indication: Cutaneous treatment of *Acne Vulgaris* of the face and/or the trunk in patients from 12 years of age and older, when many comedones, papules and pustules are present.

Proposal: Add to the formulary

Rational: To be used as a 2nd line in patients not responding to existing topical retinoid preparations; or 1st line in patients with truncal acne.

Cost: £27.75 for 75g (for 1-2 months treatment depending on the number of pump actuations used)

Likely to treat 60 patients per year cross site

Not included on the NWL Integrated Formulary for requested indication.

**Outcome: Approved for addition to the Trust Formulary**

- **Tirbanibulin 10mg/g Ointment (Klisyi<sup>®</sup>)**

Requested by: Dermatology

Indication: Field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults.

Proposal: Add to the formulary

Rational: To be used as a 1st or 2nd line treatment option for actinic keratosis. It the shortest duration treatment course (5 days) available for actinic keratosis. Picato<sup>®</sup> (Ingenol mebutate) which is on our CWFT Formulary has been discontinued and this was a shorter application treatment regime compared to all the other formulary alternatives.

Cost: £59.00 for 5 x 250mg single use sachets (one treatment cycle)

Likely to treat 50 patients per year at each hospital site.

Not included on the NWL Integrated Formulary for requested indication.



**Outcome: Approved for addition to the Trust Formulary**

**Approval for removal of Ingenol Mebutate (Picato<sup>®</sup>) from the Trust Formulary**

***Ex-Panel Applications***

- **Budesonide Orodispersible 500mcg Tablets (Jorveza<sup>®</sup>)**

Requested by: Gastroenterology

Proposal: Add formulation additional strength to formulary to as licensed product for Eosinophilic Oesophagitis (EOE) prevention of relapse following initial 12-week treatment course.

The treatment dose of 1mg BD is licensed and approved by NICE.

Licence has now been extended to cover a maintenance dose of 500mcg BD as most patients relapse at the end of the 12-week treatment course.

This was recommended in the BSG Guidelines on EoE published in 2022. <https://gut.bmj.com/content/71/8/1459>

Currently prescribing 1mg OD (Unlicensed) as only 1mg tablets available on the formulary.

Likely to treat 10 patients per year cross site

Cost: Fairly similar however use of 500mcg BD would reduce steroid exposure compared to 1mg BD.

1mg Tablets: £323 + VAT per 90 tablet pack.

**Outcome: Approved for addition to the Trust Formulary**

***Removals***

- Nil

***NICE Approved Applications***

- **TA875 Semaglutide (Wegovy<sup>®</sup>) for managing overweight and obesity**

Proposal: Add to the formulary in line with NICE TA875

**Outcome: Approved for addition to the Trust Formulary for use in line with NICE TA875**

- **TA906 Rimegepant for preventing migraine**

Proposal: Add to the formulary in line with NICE TA906

**Outcome: Approved for addition to the Trust Formulary for use in line with NICE TA906**

- **TA907 Deucravacitinib for treating moderate to severe plaque psoriasis**

Proposal: Add to the formulary in line with NICE TA907

**Outcome: Approved for addition to the Trust Formulary for use in line with NICE TA907**

***Pharmacoeconomic Board requests***

- **Infliximab Behcet's Disease**

Approved by the Pharmacoeconomic Board on 21/07/2023

**Outcome: Noted**

- **Cabotegravir for HIV**

Approved by the Pharmacoeconomic Board on 21/08/2023

**Outcome: Noted**

- **Secukinumab for Hidradenitis Suppurativa**

Approved by the Pharmacoeconomic Board on 11/09/2023

**Outcome: Noted**

- **Ustekinumab (Dose Escalation) for Crohn's Disease**

Approved by the Pharmacoeconomic Board on 11/09/2023



**Outcome: Noted**

#### **4.2 Trust Medicines Policy**

- **TMP Section 27 Process for demand management of IV Immunoglobulin**
  - Routine review and update
  - Updated to include NHS England: Commissioning Criteria Policy for the use of therapeutic immunoglobulin (Ig) England, 2021.
  - Local immunoglobulin approval panels have been replaced by Sub-Regional Immunoglobulin Approval Panels.
  - Local list of indications for sub-regional use included.
  - Appendix 1 updated
  - Appendix 2 added

It was agreed by the Group that going forward IVIG Reports no longer need to be noted at TMG going forward as TMG no longer acts as the IVIG Local Approval Panel on account of the establishment of the North West London Sub-Regional Immunoglobulin Approval Panel.

**Outcome: Approved**

#### **4.3 Medicines Optimisation**

- Nil

#### **4.4 NICE Technical Appraisals and Guidance**

##### **a) NICE Technology Appraisals**

**TA appraisals published since previous TMG meeting: 7**

**TA906 Rimegepant for preventing migraine (05/07/2023)**

**Formulary status / Action**

**Not included on the formulary**

**Application form received - See Section 4.1**

**TA907 Deucravacitinib for treating moderate to severe plaque psoriasis (28/06/2023)**

**Formulary status / Action**

**Not included on the formulary**

**Application form received - See Section 4.1**

**TA908 Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy (05/07/2023)**

**Formulary status / Action**

**Included on the formulary for another indication**

**Action: Nil - Not applicable as condition not treated at CWFT**

**TA909 Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (12/07/2023)**

**Formulary status / Action**

**Nil - Not recommended**

**TA910 Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal)**

**Formulary status / Action**

**Nil - Terminated Appraisal**

**TA911 Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer (26/07/2023)**



**Formulary status / Action**

**Included on the formulary for another indication**

**Numbers likely to treat at CWH site: 0-1 patient per year**

**Numbers likely to treat at WMUH site: 0-1 patient per year**

**TA912 Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease (15/08/2023)**

**Formulary status / Action**

**Not included on the formulary**

**Action: Nil - Not applicable as condition not treated at CWFT**

**a) NICE Highly Specialised Technology Appraisals published since last meeting**

**1 HST appraisal published since previous TMG meeting to end September 2023**

**HST27 Afamelanotide for treating erythropoietic protoporphyria  
(26/07/2023)**

**Not recommended**

**4.5 IVIG requests**

**• IVIG Issues for June 2023 - CW Site**

There were 9 IVIG issues in June 2023, with 4 new requests:

**Outcome: Noted**

**• IVIG issues for June 2023 - WMH Site**

There were 13 IVIG issues in June 2023, with 5 new requests:

**Outcome: Noted**

**• IVIG Issues for July 2023 - CW Site**

There were 14 IVIG issues in July 2023 with 7 new requests

**Outcome: Noted**

**• IVIG issues for July 2023 - WMH Site**

There were 13 IVIG issues in July 2023, with 7 new requests:

**Outcome: Noted**

It was agreed by the Group that going forward IVIG Reports no longer need to be noted at TMG going forward as TMG no longer acts as the IVIG Local Approval Panel on account of the establishment of the North West London Sub-Regional Immunoglobulin Approval Panel (See Section 4.2).

**4.6 Items for noting**

**• Quarterly Controlled Drug Summary Report - Q1 2023/24**

Quarterly Controlled Drug Summary Report for Q1 2023/24

**Outcome: Noted**

**• Quarterly Controlled Drugs Accountable Officer Report - Q1 2023/24**

Quarterly CD Accountable Officer Report for Q1 2023/24

**Outcome: Noted**

**• Medication Safety Bulletin: Cerner Medication Administration**

Medication Safety Bulletin relating to Cerner Medication Administration

**Outcome: Noted**

**• MHRA Drug Safety Update - July 2023**



MHRA update for March 2023

**Outcome: Noted**

- **MHRA Drug Safety Update - August 2023**

MHRA update for April 2023

**Outcome: Noted**

**4.7 Meeting minutes for noting**

- **HIV/GUM Medicines Sub-Group Meeting Minutes - April 2023**

Minutes from HIV/GUM Medicines Sub-Group Meeting held April 2023

**Outcome: Noted**

- **HIV/GUM Medicines Sub-Group Meeting Minutes - July 2023**

Minutes from HIV/GUM Medicines Sub-Group Meeting held July 2023

**Outcome: Noted**

- **Medication Safety Group Meeting Minutes - July 2023**

Minutes from Medication Safety Group Meeting held July 2023

**Outcome: Noted**

**5. Any other business**

Nil

**6. Date of next meeting**

**Next meeting**

**Date 11<sup>th</sup> December 2023**

**Time: 8am-9am**

**Location: via Teams**